The clinical trial will be phase II/III double-blind, randomised, placebo-controlled trial with a projected 200 panic disorder patients.
Arm 1 will include the experimental drug with patients taking an inhaler of 30% xenon, 30% oxygen and 40% nitrogen with a dose of 10L gas by volume. Arm 2 will include the placebo comparator with patients taking medical gas consisting of 30% oxygen, 70% nitrogen with a dose of 10L gas volume.
The primary outcome measure used will be the change in panic disorder rating scale from baseline to week 6. The secondary outcome measure will be the patient health questionnaire-9 from baseline to week 6.